By Karlee Weinmann (May 14, 2014, 5:22 PM EDT) -- The CEO of AstraZeneca PLC said Wednesday that his company's sale to Pfizer Inc. is "not inevitable" but could come to fruition if the New York-based suitor named a better price than its previous $106 billion offer and alleviated risks tied to the merger. In interviews with Bloomberg and Reuters, Pascal Soriot said a winning purchase price would be well above the consideration already proposed by Pfizer. The comments fanned speculation that the wannabe buyer would go hostile in its pursuit, taking its pitch straight to shareholders in a tender offer. Pfizer has been fielding questions from British officials and U.S. lawmakers over the transaction's implications. Meanwhile, AstraZeneca has stuck to its own business plan....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
